RecruitingPhase 1NCT07176208

Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults

Studying Primary orthostatic tremor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Food and Drug Administration (FDA)
Principal Investigator
Melanie Fein, MD
Spaulding Clinical Research LLC
Intervention
5 mg Dronabinol (Marinol®) + Placebo Beverage(drug)
Enrollment
48 target
Eligibility
21-55 years · All sexes
Timeline
20252026

Study locations (2)

Collaborators

Spaulding Clinical Research LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07176208 on ClinicalTrials.gov

Other trials for Primary orthostatic tremor

Additional recruiting or active studies for the same condition.

See all trials for Primary orthostatic tremor

← Back to all trials